不同剂量阿美替尼治疗表皮生长因子受体基因突变晚期非小细胞肺癌患者的临床疗效

Clinical efficacy of different doses of almonertinib in the treatment of advanced non-small cell lung cancer patients with epidermal growth factor receptor gene mutation

目的探讨不同剂量阿美替尼治疗表皮生长因子受体(EGFR)基因突变晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法根据治疗方案的不同将66例EGFR基因突变晚期NSCLC患者分为对照组(n=35)和加量组(n=31),对照组患者给予常规剂量(110 mg)阿美替尼治疗,加量组患者给予加量(165 mg)阿美替尼治疗。比较两组患者的临床疗效、临床症状缓解时间、免疫功能指标[免疫球蛋白(Ig)A、IgG、IgM]及不良反应发生情况。结果加量组患者的疾病控制率高于对照组,咳嗽、胸闷、胸痛、乏力缓解时间均短于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者IgA、IgM、IgG水平均低于本组治疗前,加量组患者IgA、IgM、IgG水平均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论阿美替尼165 mg治疗EGFR基因突变晚期NSCLC患者的疗效显著,在缓解临床症状、改善免疫功能方面更具优势,且不会增加不良反应。

Objective To investigate the clinical efficacy of different doses of almonertinib in the treatment of advanced non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)gene mutation.Method A total of 66 advanced NSCLC patients with EGFR gene mutation were divided into control group(n=35)and additional dose group(n=31)according to different treatment methods.The control group were treated with the conventional dose(110 mg)of almonertinib,and the additional group were treated with the additional dose(165 mg)of almonertinib.The clinical efficacy,clinical symptom relief time[immunoglobulin(Ig)A,IgG,IgM]and the occurrence of adverse reactions were compared between the two groups.Result The disease control rate in the additional dose group was higher than that in the control group,and the relieving time of cough,chest tightness,chest pain and fatigue were shorter than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of IgA,IgM and IgG in two groups were lower than those before treatment,and the levels of IgA,IgM and IgG in additional dose group were higher than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Almonertinib 165 mg is effective in the treatment of advanced NSCLC patients with EGFR gene mutation,and it has more advantages in relieving clinical symptoms and improving immune function,without increasing adverse reactions.